stockrow
Friday 6 November 2026
Export APYX’s income statement to Excel — free account
Apyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024.
- Revenue
- +8.95%
- EPS
- +20.0%
- Free cash flow
- +53.2%
- Total debt
- +2.74%
Quarter to September 2026, against a year earlier
2.93
0.13
−4.25%
Follow APYX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.81 | 3.37 | 2.89 | 2.72 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(66.04) | (56.41) | (282.18) | (56.85) | |
P/B ratio |
10.75 | 17.75 | 12.33 | 9.70 | |
Price to Tangible BV |
10.95 | 18.05 | 12.51 | 9.82 | |
EV/Sales |
2.13 | 3.65 | 3.12 | 2.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.39) | (21.08) | (22.14) | (19.48) | |
EV/FCF |
(14.24) | (19.32) | (19.38) | (17.10) | |
Quick Ratio |
3.74 | 4.41 | 4.65 | 4.15 | |
Current Ratio |
4.95 | 5.68 | 5.80 | 5.00 | |
Net Debt/EBITDA |
(25.51) | (4.79) | (5.58) | 13.45 | |
Debt/Assets |
57.68% | 57.85% | 55.68% | 52.16% | |
Debt/Equity |
3.54 | 3.19 | 2.68 | 2.35 | |
Asset Turnover |
1.00 | 0.98 | 0.91 | 0.80 | |
Operating CF/Net income |
0.92 | 1.08 | 0.27 | 1.95 | |
Capex/Depreciation |
(1.42) | (0.34) | (0.30) | (1.24) | |
Interest Coverage |
(0.40) | (1.30) | (0.67) | 0.01 | |
Research and Development Expense of Revenue |
6.05% | 5.71% | 6.12% | 4.93% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 71.18% | 64.62% | 57.63% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.37% | 7.74% | 2.50% | 2.61% | |
Graham Net Nets |
0.02 | 0.02 | 0.03 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.76%) | (4.45%) | (5.96%) | (7.71%) | |
Free Cash Flow Yield |
(8.24%) | (5.61%) | (5.57%) | (6.34%) | |
Revenue per Share |
0.32 | 0.32 | 0.29 | 0.47 | |
Operating CF per Share |
(0.04) | (0.08) | (0.01) | (0.06) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.04) | (0.08) | (0.01) | (0.07) | |
Cash per Share |
0.59 | 0.63 | 0.71 | 0.77 | |
Shareholders Equity per Share |
0.23 | 0.25 | 0.30 | 0.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.23 | 0.25 | 0.30 | 0.36 | |
Free Cash Flow |
(1.90) | (3.56) | (0.63) | (2.80) | |
Working Capital |
42.97 | 43.80 | 45.35 | 46.77 | |
Capital Expenditures |
(0.26) | (0.07) | (0.06) | (0.27) | |
Net Current Asset Value |
2.21 | 3.17 | 4.86 | 6.46 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.93 | 12.43 | 12.20 | 16.13 | |
Average Payables |
3.37 | 2.54 | 2.47 | 2.84 | |
Average Inventory |
10.55 | 9.47 | 8.61 | 8.08 | |
Average Assets |
59.52 | 59.63 | 61.59 | 65.84 | |
Average Common Equity |
8.06 | 9.27 | 11.87 | 14.58 |
Columns are period end dates · fundamentals updated 5 Nov 2026